Gene Mutation Analysis in EGFR Wild Type NSCLC Responsive to Erlotinib: Are There Features to Guide Patient Selection?

Tyrosine kinase inhibitors (TKIs) are very efficacious in non-small-cell lung cancer (NSCLC) patients harboring activating Epidermal Growth Factor Receptor (EGFR) mutations. However, about 10% of EGFR wild type (wt) patients respond to TKI, with unknown molecular mechanisms of sensitivity. We consid...

Descripción completa

Detalles Bibliográficos
Autores principales: Ulivi, Paola, Delmonte, Angelo, Chiadini, Elisa, Calistri, Daniele, Papi, Maximilian, Mariotti, Marita, Verlicchi, Alberto, Ragazzini, Angela, Capelli, Laura, Gamboni, Alessandro, Puccetti, Maurizio, Dubini, Alessandra, Burgio, Marco Angelo, Casanova, Claudia, Crinò, Lucio, Amadori, Dino, Dazzi, Claudio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4307273/
https://www.ncbi.nlm.nih.gov/pubmed/25561229
http://dx.doi.org/10.3390/ijms16010747

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4307273/
https://www.ncbi.nlm.nih.gov/pubmed/25561229
http://dx.doi.org/10.3390/ijms16010747

Ejemplares similares